Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 PharmaphorumNxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.NeuroscienceRead full story pharminent August 26, 2026 (Last updated: September 1, 2026) Pharmaphorum Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer’s cognition. Neuroscience Read full story Post navigation Previous: Jazz secures FDA approval for Ziihera in advanced HER2+ GEANext: Metsera backers establish new biotech armed with China-licensed immunology asset Related Stories Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Jazz secures FDA approval for Ziihera in advanced HER2+ GEA pharminent August 26, 2026
